Clinical Trial

Tumor Mutational Burden, Liquid Biopsy, Angiogenic Factors and DCE-MRI Perfusion in HPV-Negative Oropharyngeal Cancer

Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
This prospective interventional study evaluates the predictive value of tumor mutational burden, liquid biopsy biomarkers (including circulating tumor DNA), angiogenic factors, and dynamic contrast-enhanced magnetic resonance (MR) perfusion imaging in patients with HPV-negative oropharyngeal squamous cell carcinoma treated with concurrent chemoradiotherapy. The aim is to improve prediction of treatment response and disease course after treatment, support decision-making regarding optimal therapy, and potentially reduce the number of imaging examinations required during follow-up.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2026-02-06.
Trial Details
NCT Number NCT07407205
Lead Sponsor Institute of Oncology Ljubljana
Conditions Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal HPV Squamous Cell Carcinoma
Enrollment 30 participants
Start Date 2019-06-10
Primary Completion 2025-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-17